Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate.
about
Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineMorphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation to trastuzumab treatment.
P2860
Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Should adjuvant trastuzumab be ...... east cancer? A current debate.
@en
Should adjuvant trastuzumab be offered in very early-stage
@nl
type
label
Should adjuvant trastuzumab be ...... east cancer? A current debate.
@en
Should adjuvant trastuzumab be offered in very early-stage
@nl
prefLabel
Should adjuvant trastuzumab be ...... east cancer? A current debate.
@en
Should adjuvant trastuzumab be offered in very early-stage
@nl
P2860
P1433
P1476
Should adjuvant trastuzumab be ...... east cancer? A current debate.
@en
P2093
Fausto Petrelli
Sandro Barni
P2860
P2888
P304
P356
10.1007/S12032-010-9460-0
P577
2010-03-02T00:00:00Z